Elicio Therapeutics (ELTX) - Cash on Hand per Share

Elicio Therapeutics (ELTX) protects its anti-tumor vaccine developments with patents on substance transport methods to lymph nodes, effectively blocking competitors. Cash per share demonstrates the company's solvency, with the 1.09 mark reflecting the latest data. The Amphiphile AI platform and stringent FDA oversight create high barriers to entry, while development relies on grants and scientific alliances.
Comprehensive metric breakdowns and analytics for Elicio Therapeutics Inc. (ELTX)

For the biotechnological model of Elicio Therapeutics (ELTX), the volume of liquid reserves per share—calculated by dividing total cash by the number of shares outstanding—is critically important. By analyzing cash per share, an investor assesses the company's ability to fund a highly specialized staff of immunologists and the development of its clinical pipeline without emergency equity dilution.